Business
CorMedix to Participate in Upcoming Investor Conferences
BERKELEY HEIGHTS, N.J., Aug. 28, 2025 (GLOBE NEWSWIRE) -- CorMedix Inc. (“CorMedix”) (Nasdaq: CRMD), a biopharmaceutical company focused on developing and
About this update from Cormedix Inc.
BERKELEY HEIGHTS, N.J. , Aug. 28, 2025 (GLOBE NEWSWIRE) -- CorMedix Inc. (“CorMedix”) (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announced that senior management will be presenting and participating in investor meetings at upcoming investor conferences taking place in September. Cantor Global Healthcare Conference Date: September 5, 2025 Time: 8:35am Eastern Format: Fireside Chat Webcast: Link to webcast Morgan Stanley 23 rd Annual Global Healthcare Conference Date: September 10, 2025 Time: 10:45am Eastern Format: Fireside Chat Webcast: Link to webcast About CorMedix CorMedix Inc. is a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases. The Company is focused on commercializing its lead product DefenCath® (taurolidine and heparin) which was approved by the FDA on November 15, 2023 . CorMedix commercially launched DefenCath® in inpatient settings in April 2024 and in outpatient settings in July 2024 . CorMedix commenced clinical studies in Total Parenteral Nutrition and Pediatric patient populations in 2025 and also intends to develop DefenCath® as a catheter lock solution for use in other patient populations. For more information visit: www.cormedix.com . Investor Contact: Dan Ferry Managing Director LifeSci Advisors [email protected] (617) 430-7576 Source: CorMedix, Inc.